Toll-like receptor 7 agonist, Imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis

Journal of Oral Pathology and Medicine

Volumn 41, Issue 7, 2012, Pages 540-546

  Ahn, Mee Young ^a   Kwon, Seong Min ^a   Cheong, Hak Hyun ^a   Park, Jong Hwan ^b   Lee, Jun ^c   Min, Seung Ki ^c   Ahn, Sang Gun ^a   Yoon, Jung Hoon ^c  

^a Chosun University   (South Korea)

^b Konyang University   (South Korea)

^c Wonkwang University   (South Korea)

Author keywords

Apoptosis; Imiquimod; Necrosis; Oral sqaumous cell carcinoma; Toll like receptor 7

Indexed keywords

CASPASE 3; CASPASE 7; HIGH MOBILITY GROUP B1 PROTEIN; IMIQUIMOD; INTERLEUKIN 6; INTERLEUKIN 8; LACTATE DEHYDROGENASE; LIPOCORTIN 5; MESSENGER RNA; TOLL LIKE RECEPTOR 7;

APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AMINOQUINOLINES; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; HUMANS; MOUTH NEOPLASMS; NECROSIS; TOLL-LIKE RECEPTOR 7; TUMOR CELLS, CULTURED;

EID: 84864383735     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2012.01158.x     Document Type: Article

References (28)

1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
2. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy 2009; 1: 949-64.
3. Lee MS, Kim YJ. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem 2007; 76: 447-80.
4. Rydberg C, Månsson A, Uddman R, Riesbeck K, Cardell LO. Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas. Immunology 2009; 128: e600-11.
5. Tsan MF. Toll-like receptors, inflammation and cancer. Semin Cancer Biol 2006; 16: 32-7.
6. Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett 2009; 14: 248-72.
7. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009; 9: 57-63.
8. Du X, Poltorak A, Wei Y, et al. Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur Cytokine Netw 2000; 11: 362-71.
9. Bourquin C, Hotz C, Noerenberg D, et al. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer Res 2011; 71: 5123-33.
10. Fleming CJ, Bryden AM, Evans A, et al. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol 2004; 151: 485-8.
11. Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005; 141: 467-73.
12. Rogers SN, Brown JS, Woolgar JA, et al. Survival following primary surgery for oral cancer. Oral Oncol 2009; 45: 201-11.
13. Kademani D. Oral cancer. Mayo Clin Proc 2007; 82: 878-87.
14. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008; 59: 1143-54.
15. Hopper C, Kubler A, Lewis H, et al. mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma. Int J Cancer 2004; 111: 138-46.
16. Park JH, Yoon HE, Jeon DI, et al. Activation of TLR2 and TLR5 did not affect tumor progression of an oral squamous cell carcinoma, YD-10B cells. J Oral Pathol Med 2010; 39: 781-5.
17. Schön MP, Schön M. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 2004; 9: 291-8.
18. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85: 85-95.
19. Weeks CE, Gibson SJ. Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro. J Interferon Res 1994; 14: 81-5.
20. Sidky YA, Borden EC, Weeks CE, et al. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res 1992; 52: 3528-33.
21. Huang SW, Liu KT, Chang CC, et al. Imiquimod simultaneously induces autophagy and apoptosis in human basal cell carcinoma cells. Br J Dermatol 2010; 163: 310-20.
22. Smith EB, Schwartz M, Kawamoto H, et al. Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J Urol 2007; 177: 2347-51.
23. McLaughlin PJ, Pothering CA, Immonen JA, et al. Topical treatment with the opioid antagonist naltrexone facilitates closure of full-thickness wounds in diabetic rats. Exp Biol Med 2011; 236: 1122-32.
24. Amaravadi RK, Thompson CB. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 2007; 13: 7271-9.
25. Nieminen A-L, Gores GJ, Wray BE, Tanaka Y, Herman B, Lemasters JJ. Calcium dependence of bleb formation and cell death in hepatocytes. Cell Calcium 1988; 9: 237-46.
26. Herman B, Nieminen AL, Gores GJ, et al. Irreversible injury in anoxic hepatocytes precipitated by an abrupt increase in plasma membrane permeability. FASEB J 1988; 2: 146-51.
27. Raucci A, Palumbo R, Bianchi ME. HMGB1: a signal of necrosis. Autoimmunity 2007; 40: 285-9.
28. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-5.